Miller Anestesia

60. Wolman RL, Nussmeier NA, Aggarwal A, et al:

Cerebral injury after cardiac surgery: Identifica-

tion of a group at extraordinary risk. Multicenter

Study of Perioperative Ischemia Research Group

(McSPI) and the Ischemia Research Education

Foundation (IREF) Investigators. Stroke 30:514–

522, 1999.

61. Bucerius J, Gummert JF, Borger MA, et al: Stroke

after cardiac surgery: A risk factor analysis of 16,184

consecutive adult patients. Ann Thorac Surg

75:472–478, 2003.

62. Newman MF, Kirchner JL, Phillips-Bute B, et al:

Longitudinal assessment of neurocognitive function

after coronary-artery bypass surgery. N Engl J Med

344:395–402, 2001.

63. Andrew MJ, Baker RA, Bennetts J, et al: A compa-

rison of neuropsychologic deficits after extracardiac

and intracaradiac surgery. J Cardiothorac Vasc

Anesth 15:9–14, 2001.

64. Neville MJ, Butterworth J, James RL, et al: Similar

neurobehavioral outcome after valve or coronary

artery operations despite differing carotid embolic

counts. J Thorac Cardiovasc Surg 121:125–136,

2001.

65. Währborg P, Booth JE, Clayton T, et al: Neuropsy-

chological outcome after percutaneous coronary

intervention or coronary artery bypass grafting:

Results from the Stent or Surgery (SoS) Trial. Cir-

culation 110:3411–3417, 2004.

66. Edmonds HL, Jr: Monitoring the nervous system

during cardiac and vascular surgery. Semin Cardio-

thorac Vasc Anesth 8:59–60, 2004.

67. Katz ES, Tunick PA, Rusinek H, et al: Protruding

aortic atheromas predict stroke in elderly patients

undergoing cardiopulmonary bypass: Experience

with intraoperative transesophageal echocardiogra-

phy. J Am Coll Cardiol 20:70–77, 1992.

68. Hartman GS, Yao FS, Bruefach M III, et al: Severity

of aortic atheromatous disease diagnosed by tran-

sesophageal echocardiography predicts stroke and

other outcomes associated with coronary artery

surgery: A prospective study. Anesth Analg 83:701–

708, 1996.

69. Davila-Roman VG, Barzilai B, Wareing TH, et al:

Atherosclerosis of the ascending aorta: Prevalence

and role as an independent predictor of cerebrovas-

cular events in cardiac patients. Stroke 25:2010–

2016, 1994.

70. Gold JP, Torres KE, Maldarelli W, et al: Improving

outcomes in coronary surgery: The impact of echo-

directed aortic cannulation and perioperative

hemodynamic management in 500 patients. Ann

Thorac Surg 78:1579–1585, 2004.

71. Wilson MJ, Boyd SY, Lisagor PG, et al: Ascending

aortic atheroma assessed intraoperatively by epiaor-

tic and transesophageal echocardiography. Ann

Thorac Surg 70:25–30, 2000.

72. Sylivris S, Calafiore P, Matalanis G, et al: The intrao-

perative assessment of ascending aortic atheroma:

Epiaortic imaging is superior to both transesopha-

geal echocardiography and direct palpation. J Car-

diothorac Vasc Anesth 11:704–707, 1997.

73. Pugsley W, Klinger L, Paschalis C, et al: The impact

of microemboli during cardiopulmonary bypass on

neuropsychological functioning. Stroke 25:1393–

1399, 1994.

74. Doblar DD: Intraoperative transcranial ultrasonic

monitoring for cardiac and vascular surgery. Semin

Cardiothorac Vasc Anesth 8:127–145, 2004.

75. Estrera AL, Garami Z, Miller CC III, et al: Cerebral

monitoring with transcranial Doppler ultrasono-

graphy improves neurologic outcome during repairs

of acute type A aortic dissection. J Thorac Cardio-

vasc Surg 129:277–285, 2005.

76. Sear JW: Kidney dysfunction in the postoperative

period. Br J Anaesth 95:20–32, 2005.

77. Gamoso MG, Phillips-Bute B, Landolfo KP, et al:

Off-pump versus on-pump coronary artery bypass

surgery and postoperative renal dysfunction.

Anesth Analg 91:1080–1084, 2000.

78. Baker RC, Armstrong MA, Allen SJ, et al: Role of the

kidney in perioperative inflammatory responses. Br

J Anaesth 88:330–334, 2002.

79. Gormley SM, McBride WT, Armstrong MA, et al:

Plasma and urinary cytokine homeostasis and renal

dysfunction during cardiac surgery. Anesthesiology

93:1210–1216, 2000.

80. Solomon R, Werner C, Mann D, et al: Effects of

saline, mannitol, and furosemide to prevent acute

decreases in renal function induced by radiocon-

trast agents. N Engl J Med 331:1416–1420, 1994.

81. Bove T, Calabro MG, Landoni G, et al: The inci-

dence and risk of acute renal failure after cardiac

surgery. J Cardiothorac Vasc Anesth 18:442–445,

2004.

82. Asimakopoulos G, Karagounis AP, Valencia O, et al:

Renal function after cardiac surgery off- versus

on-pump coronary artery bypass: Analysis using

the Cockroft-Gault formula for estimating creati-

nine clearance. Ann Thorac Surg 79:2024–2031,

2005.

83. Mangano CM, Diamondstone LS, Ramsay JG, et al:

Renal dysfunction after myocardial revasculariza-

tion: Risk factors, adverse outcomes, and hospital

resource utilization. The Multicenter Study of Perio-

perative Ischemia Research Group. Ann Intern Med

128:194–203, 1998.

84. Rassias AJ: Intraoperative management of hyper-

glycemia in the cardiac surgical patient. Semin

Thorac Cardiovasc Surg 18:330–338, 2006.

85. Wade AO, Cordingley JJ: Glycaemic control in cri-

tically ill patients with cardiovascular disease. Curr

Opin Crit Care 12:437–443, 2006.

86. Van den Berghe G: Does tight blood glucose control

during cardiac surgery improve patient outcome?

Ann Intern Med 146:307–308, 2007.

87. Gandhi GY, Nuttall GA, Abel MD, et al: Intensive

intraoperative insulin therapy versus conventional

glucose management during cardiac surgery: A

randomized trial. Ann Intern Med 146:233–243,

2007.

88. Streeter NB: Considerations in prevention of surgi-

cal site infections following cardiac surgery: When

your patient is diabetic. J Cardiovasc Nurs 21:E14–

E20, 2006.

89. Bennett-Guerrero E, Jimenez JL, White WD, et al:

Cardiovascular effects of intravenous triiodothyro-

nine in patients undergoing coronary artery bypass

graft surgery: A randomized, double-blind, placebo-

controlled trial. Duke T3 Study Group. JAMA

275:687–692, 1996.

90. Eagle KA, Guyton RA, Davidoff R, et al: ACC/AHA

2004 guideline update for coronary artery bypass

graft surgery: A report of the American College of

Cardiology/American Heart Association Task Force

on Practice Guidelines (Committee to Update the

1999 Guidelines for Coronary Artery Bypass Graft

Surgery). Circulation 110:e340–e437, 2004.

91. Zindrou D, Taylor KM, Bagger JP: Excess coronary

artery bypass graft mortality among women with

hypothyroidism. Ann Thorac Surg 74:2121–2125,

2002.

92. Christakis GT, Weisel RD, Buth KJ, et al: Is body size

the cause for poor outcomes of coronary artery

bypass operations in women? J Thorac Cardiovasc

Surg 110:1344–1356, 1995.

93. Grady D, Herrington D, Bittner V, et al: Cardiovas-

cular disease outcomes during 6.8 years of hormone

therapy: Heart and Estrogen/Progestin Replace-

ment Study follow-up (HERS II). JAMA 288:49–57,

2002.

94. Herrington DM, Reboussin DM, Brosnihan KB,

et al: Effects of estrogen replacement on the pro-

gression of coronary-artery atherosclerosis. N Engl

J Med 343:522–529, 2000.

95. Hulley S, Grady D, Bush T, et al: Randomized trial

of estrogen plus progestin for secondary prevention

of coronary heart disease in postmenopausal

women. Heart and Estrogen/Progestin Replace-

ment Study (HERS) Research Group. JAMA

280:605–613, 1998.

96. Nussmeier NA, MarinoMR, VaughnWK: Hormone

replacement therapy is associated with improved

survival in women undergoing coronary artery

bypass grafting. JThorac Cardiovasc Surg 124:1225–

1229, 2002.

97. Shackelford DP, Daniels S, Hoffman MK, et al:

Estrogen therapy in women undergoing coronary

artery bypass grafting: Effect on surgical complica-

tions. Obstet Gynecol 95:732–735, 2000.

98. Sullivan JM, El-Zeky F, Vander Zwaag R, et al: Effect

on survival of estrogen replacement therapy after

coronary artery bypass grafting. Am J Cardiol

79:847–850, 1997.

99. Nussmeier NA, Mora-Mangano C, Fontes M, et al:

Hormone replacement therapy is safe in women

undergoing coronary artery bypass grafting. Tex

Heart Inst J 32:507–514, 2005.

100. Hartmann M, Sucker C, Boehm O, et al: Effects of

cardiac surgery on hemostasis. Transfus Med Rev

20:230–241, 2006.

101. Shander A, Moskowitz D, Rijhwani TS: The safety

and efficacy of “bloodless” cardiac surgery. Semin

Cardiothorac Vasc Anesth 9:53–63, 2005.

102. Herbertson M: Recombinant activated factor VII in

cardiacsurgery.BloodCoagulFibrinolysis15(Suppl1)

S31–S32, 2004.

103. Michalopoulos A, Tzelepis G, Dafni U, et al: Deter-

minants of hospital mortality after coronary artery

bypass grafting. Chest 115:1598–1603, 1999.

104. Leal-Noval SR, Rincon-Ferrari MD, Garcia-Curiel

A, et al: Transfusion of blood components and

postoperative infection in patients undergoing

cardiac surgery. Chest 119:1461–1468, 2001.

105. Vamvakas EC, Carven JH: Allogeneic blood trans-

fusion and postoperative duration of mechanical

ventilation: Effects of red cell supernatant, platelet

supernatant, plasma components and total transfu-

sed fluid. Vox Sang 82:141–149, 2002.

106. Ranucci M, Pavesi M, Mazza E, et al: Risk factors for

renal dysfunction after coronary surgery: The role

of cardiopulmonary bypass technique. Perfusion

9:319–326, 1994.

107. Koch CG, Khandwala F, Li L, et al: Persistent effect

of red cell transfusion on health-related quality of

life after cardiac surgery. AnnThorac Surg 82:13–20,

2006.

108. Hirsh J, Warkentin TE, Shaughnessy SG, et al:

Heparin and low-molecular-weight hepar: Mecha-

nisms of action, pharmacokinetics, dosing, monito-

ring, efficacy safety. Chest 119:64S–94S, 2001.

109. Hirsh J, Anand SS, Halperin JL, et al: Guide to anti-

coagulant therapy: Heparin: A statement for health-

care professionals from the American Heart

Association. Circulation 103:2994–3018, 2001.

109a. Bull BS, HuseWM, Brauer FS, et al: Heparin therapy

during extracorporeal circulation. II. The use of a

dose-respone curve to individualize heparain and

protamine dosage. J Thorac Cardiovasc Surg

69:685–689, 1975.

110. Young JA, Kisker CT, Doty DB: Adequate anticoa-

gulation during cardiopulmonary bypass determi-

ned by activated clotting time and the appearance

of fibrin monomer. Ann Thorac Surg 26:231–240,

1978.

111. Doty DB, Knott HW, Hoyt JL, et al: Heparin dose

for accurate anticoagulation in cardiac surgery. J

Cardiovasc Surg (Torino) 20:597–604, 1979.

112. Shore-Lesserson L: Evidence based coagulation

monitors: Heparin monitoring, thromboelastogra-

phy, and platelet function. Semin Cardiothorac Vasc

Anesth 9:41–52, 2005.

113. Aggarwal A, Sobel BE, Schneider DJ: Decreased

platelet reactivity in blood anticoagulated with

bivalirudin or enoxaparin compared with unfrac-

tionated heparin: Implications for coronary inter-

vention. J Thromb Thrombolysis 13:161–165, 2002.

114. Despotis GJ, Summerfield AL, Joist JH, et al: Com-

parison of activated coagulation time and whole

blood heparin measurements with laboratory

plasma anti-Xa heparin concentration in patients

having cardiac operations. JThorac Cardiovasc Surg

108:1076–1082, 1994.

115. Shore-Lesserson L: Coagulation monitoring. In

Kaplan JA, Reich DL, Lake CL, et al (eds): Kaplan’s

Cardiac Anesthesia, 5th ed. Philadelphia, Elsevier

Saunders, 2006, pp 557–583.

116.

DespotisGJ,JoistJH,HogueCWJr

,etal:Moreeffec

tive suppression of hemostatic system activation in

Anestesia para los procedimientos de cirugía cardíaca

1733

Sección IV

Anestesia por subespecialidades en el adulto